| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/17/2013 | US20130018053 Substituted pyrimidines |
| 01/17/2013 | US20130018052 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors |
| 01/17/2013 | US20130018051 Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| 01/17/2013 | US20130018050 Bi-functional pyrazolopyridine compounds |
| 01/17/2013 | US20130018049 Azaindole Compounds and Methods for Treating HIV |
| 01/17/2013 | US20130018048 Oxazole derivatives useful as modulators of faah |
| 01/17/2013 | US20130018047 N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
| 01/17/2013 | US20130018046 Acetylenic Heteroaryl Compounds |
| 01/17/2013 | US20130018045 New Chemical Entities To Be Used For Wee1 Inhibition For The Treatment Of Cancer |
| 01/17/2013 | US20130018044 New inhibitors of cyclophilins and uses thereof |
| 01/17/2013 | US20130018043 Aminomethyl quinolone compounds |
| 01/17/2013 | US20130018042 Toll-Like Receptor Agonist Formulations and Their Use |
| 01/17/2013 | US20130018041 Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases |
| 01/17/2013 | US20130018040 Compositions And Methods For Treating Toxoplasmosis, Cryptosporidiosis, And Other Apicomplexan Protozoan Related Diseases |
| 01/17/2013 | US20130018039 Imidazolyl-imidazoles as kinase inhibitors |
| 01/17/2013 | US20130018038 Chemical compounds |
| 01/17/2013 | US20130018037 Compounds - 801 |
| 01/17/2013 | US20130018036 Substituted indazole derivatives active as kinase inhibitors |
| 01/17/2013 | US20130018035 Compounds useful as inhibitors of atr kinase |
| 01/17/2013 | US20130018034 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| 01/17/2013 | US20130018033 Raf inhibitor compounds and methods of use thereof |
| 01/17/2013 | US20130018032 Inhibitors of bruton's tyrosine kinase |
| 01/17/2013 | US20130018031 Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists |
| 01/17/2013 | US20130018030 New compounds, pharmaceutical compositions and uses thereof |
| 01/17/2013 | US20130018029 High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds |
| 01/17/2013 | US20130018028 Bi-(indole-2-aceto)-iron II (Ferrous Indole Acetate) |
| 01/17/2013 | US20130018027 Compositions and methods for non-toxic delivery of antiprogestins |
| 01/17/2013 | US20130018026 Halogenated phenols for diagnostics, antioxidant protection and drug delivery |
| 01/17/2013 | US20130018025 Anticancer Compound |
| 01/17/2013 | US20130018024 Methods and systems for pharmacogenomic treatment of cardiovascular conditions |
| 01/17/2013 | US20130018023 Compositions for topical administration |
| 01/17/2013 | US20130018022 Pharmaceutical composition including a testis extract as an active ingredient for treating and preventing anemia |
| 01/17/2013 | US20130018021 2Alpha-Methyl and 2Beta-Methyl Analogs of 19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Their Uses |
| 01/17/2013 | US20130018020 Inhibitor for melanin, and cosmetic composition containing same |
| 01/17/2013 | US20130018019 Aromatic compounds having sphingosine-1-phosphonate (s1p) receptor activity |
| 01/17/2013 | US20130018018 Novel nucleoside phosphonates and analogs |
| 01/17/2013 | US20130018017 Quinolinone derivatives as parp and tank inhibitors |
| 01/17/2013 | US20130018016 Agent for Combating Ectoparasites |
| 01/17/2013 | US20130018015 Nutritional Composition and Methods of Making and Using Same |
| 01/17/2013 | US20130018014 New class of therapeutics that enhance small molecule diffusion |
| 01/17/2013 | US20130018013 Bicyclic nucleosides and nucleotides as therapeutic agents |
| 01/17/2013 | US20130018012 Lipid composition for improving brain function |
| 01/17/2013 | US20130018011 Method of treating dengue fever |
| 01/17/2013 | US20130018010 Polymeric conjugates of adenine nucleoside analogs |
| 01/17/2013 | US20130018009 Anti-obesity product and its method of preparation |
| 01/17/2013 | US20130018008 Crystalline forms of a macrolide, and uses therefor |
| 01/17/2013 | US20130018007 Modified Saponins for the Treatment of Fungal Infections |
| 01/17/2013 | US20130018006 Atheroscleroclastic Bioceutical Formulations |
| 01/17/2013 | US20130018005 Glycoside derivatives and uses thereof |
| 01/17/2013 | US20130018003 Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles |
| 01/17/2013 | US20130018002 Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles |
| 01/17/2013 | US20130018001 Methods of diagnosing cancer |
| 01/17/2013 | US20130017999 Methods and Compositions for Evaluating and/or Treating Chronic Immune Diseases |
| 01/17/2013 | US20130017998 Novel modified galectin 9 proteins and use thereof |
| 01/17/2013 | US20130017993 Glycoside derivatives and uses thereof |
| 01/17/2013 | US20130017950 5,8-difluoro-4-(2-(4-(heteroaryloxy)-phenyl)ethylamino)quinazolines and their use as agrochemicals |
| 01/17/2013 | US20130017616 Methods For Treating Inflammation |
| 01/17/2013 | US20130017565 Methods and products related to low molecular weight heparin |
| 01/17/2013 | US20130017284 Compositions and methods for modulating metabolic pathways |
| 01/17/2013 | US20130017283 Compositions and methods for modulating metabolic pathways |
| 01/17/2013 | US20130017280 Composition for accelerating change in muscle type |
| 01/17/2013 | US20130017273 Compounds useful as inhibitors of atr kinase |
| 01/17/2013 | US20130017272 Method for treating non-small cell lung cancer |
| 01/17/2013 | US20130017268 Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof |
| 01/17/2013 | US20130017267 Method of making particles for use in a pharmaceutical composition |
| 01/17/2013 | US20130017265 Particles for multiple agent delivery |
| 01/17/2013 | US20130017263 Gastric acid secretion inhibiting composition |
| 01/17/2013 | US20130017262 Immediate/delayed drug delivery |
| 01/17/2013 | US20130017259 Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients |
| 01/17/2013 | US20130017258 Self-microemulsifying mitotane composition |
| 01/17/2013 | US20130017257 Dry powder formulation containing tiotropium for inhalation |
| 01/17/2013 | US20130017256 Methods of treating hypertriglyceridemia |
| 01/17/2013 | US20130017255 Tamper Resistant Dosage Form Comprising an Adsorbent and an Adverse Agent |
| 01/17/2013 | US20130017254 Pharmaceutical formulation containing phenytoin sodium and magnesium stearate |
| 01/17/2013 | US20130017252 Method for Selectively Inhibiting the Activity of ACAT1 in the Treatment of Alzheimer's Disease |
| 01/17/2013 | US20130017249 COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY |
| 01/17/2013 | US20130017247 Treatment and/or prevention of oral allergic symptoms caused by oral contact with fruits and/or vegetables |
| 01/17/2013 | US20130017244 Sustained release intraocular implants and related methods |
| 01/17/2013 | US20130017243 Sustained-release reservoir implants for intracameral drug delivery |
| 01/17/2013 | US20130017234 Implant modified with non-hydroxylated vitamin d precursors |
| 01/17/2013 | US20130017231 Composition for Forming a Temporary Intestinal Occlusion in a Mammal |
| 01/17/2013 | US20130017229 Active scaffolds for on-demand drug and cell delivery |
| 01/17/2013 | US20130017224 Nucleic Acid Molecules Encoding Rantes, and Compositions Comprising and Methods of Using the Same |
| 01/17/2013 | US20130017223 Methods and compositions for delivery of nucleic acids |
| 01/17/2013 | US20130017211 Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
| 01/17/2013 | US20130017204 Genes of an Otitis Media Isolate of Nontypeable Haemophilus Influenzae |
| 01/17/2013 | US20130017203 Methods of treating and preventing staphylococcus aureus infections and associated conditions |
| 01/17/2013 | US20130017198 Manipulation of calcium channels to regulate after-depolarization events in cardiac myocytes |
| 01/17/2013 | US20130017196 Substituted imidazole derivatives |
| 01/17/2013 | US20130017194 Fak inhibitors |
| 01/17/2013 | US20130017190 Treatment of inflammatory diseases |
| 01/17/2013 | US20130017189 Functionalised Triblock Copolymers and Compositions Containing Such Polymers |
| 01/17/2013 | US20130017188 Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses |
| 01/17/2013 | US20130017183 Compositions containing non-polar compounds |
| 01/17/2013 | US20130017182 Multi-criteria optimized dietary supplement formulations |
| 01/17/2013 | US20130017172 Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells With a Virus |
| 01/17/2013 | US20130017171 Methods and compositions for treating hepatitis c virus |
| 01/17/2013 | US20130017170 Substituted pyrrolo-pyrazole derivatives as kinase inhibitors |
| 01/17/2013 | US20130017167 Hydrophobic block conjugated therapeutic agents |
| 01/17/2013 | US20130017166 Protein-Poly(2-oxazoline) Conjugates for Enhanced Cellular Delivery and Transport Across Biological Barriers |